Evolving field of immunotherapy: pioneering new paths in SCLC by Antonious Ziad Hazim et al.
JCO Oncology Practice shared an article by Antonious Ziad Hazim et al., titled:
“Evolving Field of Immunotherapy: Pioneering New Paths in Small-Cell Lung Cancer”
Authors: Antonious Ziad Hazim, Konstantinos Leventakos, Vinicius Ernani.
Small-cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid tumor growth and early metastasis. It accounts for approximately 15% of all lung cancers and is strongly linked to tobacco exposure. Although most patients initially respond to systemic therapy, resistance develops quickly, leading to early relapse.
The prognosis for metastatic SCLC remains poor, underscoring the urgent need for more effective treatments. While the introduction of targeted therapies and immunotherapies has transformed the management of non-small cell lung cancer (NSCLC), their application in SCLC has been limited by the disease’s molecular and genomic complexity.
Despite these obstacles, novel immunomodulatory agents have shown potential and are undergoing clinical investigation. This review examines the current role of immunotherapy in SCLC and explores emerging therapeutic strategies.
Read more posts about Immune Oncology on oncodaily.com.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023